Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

Table 4 Summary of the adverse events

Adverse events	Number of studies	Erenumab		Placebo		Risk Ratio (95%CI)	P Value
Adverse events	Number of studies	Events	Total	Events	Total	Risk Ratio (95%CI)	P Value
Any adverse event	12	1475	2914	1113	2219	1.02 [0.94, 1.11]	0.63
Any serious adverse event	11	45	2809	37	2183	0.90 [0.58, 1.39]	0.62
Any adverse event leading to treatment discontinuation	11	30	2908	19	2183	1.07 [0.59, 1.92]	0.82
Nasopharyngitis	10	243	2765	182	2053	0.93 [0.77, 1.12]	0.45
Upper respiratory tract infection	8	99	2365	67	1786	1.09 [0.80, 1.48]	0.60
Constipation	7	102	2534	28	1770	2.53 [1.60, 4.02]	< 0.0001*
Nausea	5	34	1626	29	1166	0.90 [0.54, 1.50]	0.69
Urinary tract infection	4	14	1520	8	1013	0.90 [0.40, 2.06]	0.81
Back Pain	4	25	988	19	727	1.05 [0.57, 1.93]	0.88
Influenza	3	24	1022	21	761	0.96 [0.52, 1.77]	0.90
Injection site pain	4	49	1413	23	1014	1.76 [0.96, 3.25]	0.07
Abdominal pain	4	10	882	2	547	2.05 [0.54, 7.72]	0.29
Vomiting	3	3	610	2	411	1.00 [0.20, 5.03]	1.00
Diarrhea	4	9	468	7	413	1.12 [0.22, 5.60]	0.89
Migraine	4	24	1400	23	1043	0.88 [0.38, 2.08]	0.78
Arthralgia	3	17	745	11	478	1.05 [0.34, 3.23]	0.94
Fatigue	4	30	1141	19	885	1.26 [0.71, 2.22]	0.43
Gastroenteritis	4	12	967	9	608	0.90 [0.39, 2.08]	0.81

ISSN: 1746-160X